Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.06. | Curasight A/S announces outcome of T03 warrant exercise | 2 | Cision News | ||
18.06. | Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT in brain cancer patients | 1 | Cision News | ||
CURASIGHT Aktie jetzt für 0€ handeln | |||||
13.06. | Spotlight Stock Market: Market Notice 110/25 - Last day of trading in Curasight A/S's subscription option CURAS TO 3 | 1 | Cision News | ||
03.06. | CURASIGHT: The exercise period commences for warrants of series TO3 on 4 June 2025 | 1 | Cision News | ||
02.06. | Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue | 1 | Cision News | ||
28.05. | CURASIGHT: Completed registration of rights issue | 1 | Cision News | ||
28.05. | Resolutions of the Annual General Meeting 2025 of Curasight A/S | 1 | Cision News | ||
21.05. | Curasight announces outcome in rights issue | 1 | Cision News | ||
15.05. | Subscription of new shares in the Right Issue 2025 exercised by Curasight management | 1 | Cision News | ||
13.05. | CURASIGHT: Notice of Annual General Meeting 2025 | 1 | Cision News | ||
13.05. | Last day of the subscription period in Curasight's rights issue of shares | 2 | Cision News | ||
07.05. | Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer | 2 | Cision News | ||
06.05. | Curasight's rights issue subscription period has commenced | 2 | Cision News | ||
02.05. | THE SUBSCRIPTION PERIOD IN CURASIGHT'S RIGHTS ISSUE OF SHARES BEGINS TODAY | 2 | Cision News | ||
30.04. | Curasight to present at HC Andersen Capital | 2 | Cision News | ||
29.04. | Curasight A/S publishes disclosure document regarding rights issue | 2 | Cision News | ||
28.04. | Spotlight Stock Market: Market Notice 73/25 - Information regarding the rights issue from Curasight A/S | 2 | Cision News | ||
25.04. | CURASIGHT: Annual Report for the fiscal year 2024 | 1 | Cision News | ||
25.04. | CURASIGHT: Interim report Q1 2025 | 1 | Cision News | ||
24.04. | CURASIGHT A/S ANNOUNCES FINAL TERMS OF RIGHTS ISSUE | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,620 | -1,34 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
JANUX THERAPEUTICS | 22,830 | +1,11 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
EVOTEC | 6,778 | +1,35 % | Aktien KW 31 Schwache Zahlen, BAFin, Zollhammer 2.0, Arbeitsmarktzahlen - jetzt Sommerloch? News. Cancom. Mutares. Evotec. SFC Energy. GEA Group. Knorr Bremse. Fuchs. Nemetschek. Villeroy & Boch. Befesa. KION. SAF Holland. Nordex. STEYR Motors. mVise. The | Aktien: Diese Woche ging es eigentlich noch ganz entspannt los, die 24.000er Mauer umkämpft, aber der Markt schien relativ sicher gegen tiefe Abstürze, Donnerstag schloss der Juli noch mit einem kleinen... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 46,240 | -2,69 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 32,150 | -2,90 % | Gold Fields, Kiniksa Join Best Stock Lists As They Defy Slump And Shares Pop: See New Names On IBD 50, IPO Leaders And More | ||
COGENT BIOSCIENCES | 10,960 | +0,83 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
ARS PHARMACEUTICALS | 17,500 | -0,85 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
ADMA BIOLOGICS | 16,525 | -1,34 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 6,100 | +1,16 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
ARCELLX | 70,53 | -0,87 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
AMYLYX PHARMACEUTICALS | 7,640 | -2,55 % | Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline | ||
SUMMIT THERAPEUTICS | 28,675 | +2,16 % | Summit Therapeutics: Ivonescimab zeigt überlegenes progressionsfreies Überleben gegenüber Pembrolizumab | ||
TANGO THERAPEUTICS | 6,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen |